Familial medullary thyroid carcinoma: genes and variants
Explore variant evidence for Familial medullary thyroid carcinoma across 2 analyzed proteins (RET, NTRK1). Linked ClinVar records include 13 pathogenic or likely pathogenic variants, 80 variants of uncertain significance and 39 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Familial medullary thyroid carcinoma
RET: Proto-oncogene tyrosine-protein kinase receptor Ret
Its activation by GDNF-family ligands guides development of the enteric nervous system, kidney, and other tissues. Activating variants cause multiple endocrine neoplasia type 2 and can drive cancer, whereas loss-of-function variants are an important cause of Hirschsprung disease.
13 ClinVar pathogenic / likely pathogenic and 106 uncertain variants in RET have source records linked to Familial medullary thyroid carcinoma. Association strength is not clinical gene validity.
NTRK1: High affinity nerve growth factor receptor
Nerve-growth-factor signaling through this pathway supports survival and differentiation of sensory and sympathetic neurons. Loss-of-function variants cause congenital insensitivity to pain with anhidrosis, whereas oncogenic NTRK1 fusions can drive diverse cancers.
0 ClinVar pathogenic / likely pathogenic and 13 uncertain variants in NTRK1 have source records linked to Familial medullary thyroid carcinoma. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Familial medullary thyroid carcinoma
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| RET C618G | 618 | Extracellular | Pathogenic / likely pathogenic (★★) |
| RET V804L | 804 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| RET V804M | 804 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| RET S891A | 891 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| RET C634Y | 634 | Extracellular | Pathogenic / likely pathogenic (★★) |
| RET F555C | 555 | Extracellular | Pathogenic / likely pathogenic (★★) |
| RET C620Y | 620 | Extracellular | Pathogenic / likely pathogenic (★★) |
| RET L790F | 790 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| RET K424N | 424 | Cadherin-like region 4 (CLD4) | Pathogenic / likely pathogenic (★★) |
| RET K666N | 666 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| RET S891L | 891 | Protein kinase | Pathogenic / likely pathogenic (★) |
| RET S649L | 649 | Transmembrane | Pathogenic / likely pathogenic (★) |
| RET R972G | 972 | Protein kinase | Pathogenic / likely pathogenic (★) |
Which prediction tools work for Familial medullary thyroid carcinoma
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 96 out of 100
- MetaLR: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 93 out of 100
- PolyPhen-2: 93 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 92 out of 100
- ESM1b (LLR): 92 out of 100
- phyloP: 70 out of 100
- SpliceAI: 53 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 49 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Multiple endocrine neoplasia also has ClinVar records linked to RET variants; they fall mostly in different places as the Familial medullary thyroid carcinoma variants (53 pathogenic / likely pathogenic).
- Hirschsprung disease also has ClinVar records linked to RET variants; they fall mostly in different places as the Familial medullary thyroid carcinoma variants (22 pathogenic / likely pathogenic).
- MEN2 phenotype: Unclassified also has ClinVar records linked to RET variants; they fall partly in the same places as the Familial medullary thyroid carcinoma variants (5 pathogenic / likely pathogenic).
Diseases related to Familial medullary thyroid carcinoma
- Ovarian cancer, also linked to NTRK1 and RET
- Colorectal cancer, also linked to NTRK1 and RET
- Non-small cell lung carcinoma, also linked to NTRK1 and RET
- Charcot-Marie-Tooth disease, also linked to NTRK1
- Multiple endocrine neoplasia, also linked to RET
- Gastrointestinal stromal tumor, also linked to RET
- Pheochromocytoma, also linked to RET
- Hereditary insensitivity to pain with anhidrosis, also linked to NTRK1
- Hirschsprung disease, also linked to RET
- Hepatocellular carcinoma, also linked to RET
- Familial hyperparathyroidism or Hypocalciuric hypercalcaemia, also linked to RET
- MEN2 phenotype: Unclassified, also linked to RET
Frequently asked questions
Which genes have records linked to Familial medullary thyroid carcinoma?
This view contains 2 analyzed proteins: RET, NTRK1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 13 pathogenic or likely pathogenic variants, 80 variants of uncertain significance and 39 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 138 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center